Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CASP7	840	EMRICASAN	CHEMBL197672	inhibitor	ChemblInteractions, DrugBank

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CASP7	rs2227310	CG + GG	paclitaxel	efficacy	yes	Patients with the CG and GG genotypes had increased overall survival time compared to those with the CC genotype. This was a stratified analysis of only people taking paclitaxel, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes CG + GG are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	22441531	981502673
CASP7	rs4353229	CC + CT	paclitaxel	efficacy	yes	Patients with the CC and CT genotypes had increased overall survival time compared to those with the TT genotype. This was a stratified analysis of only people taking paclitaxel, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes CC + CT are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	22441531	981502653
CASP7	rs7921977	CT	docetaxel	efficacy	yes	Patients with the CT genotype had reduced progression-free survival compared to those with the TT genotype. Please note alleles have been complemented to the plus chromosomal strand.	Genotype CT is associated with decreased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	22441531	981502089
CASP7	rs12415607	AA + AC	paclitaxel	efficacy	yes	Patients with the AA and AC genotypes had increased overall survival time compared to those with the CC genotype. This was a stratified analysis of only people taking paclitaxel, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes AA + AC are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	22441531	981502641
CASP7	rs7921977	CC	docetaxel	efficacy	yes	No significant difference in progression-free survival was seen between patients with the CC genotype and those with the TT genotype. Please note alleles have been complemented to the plus chromosomal strand.	Genotype CC is not associated with response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	22441531	1183554747
CASP7	rs2227310	CG + GG	docetaxel	efficacy	yes	Patients with the CG and GG genotypes had increased overall survival time compared to those with the CC genotype. p-value remained significant after Bonferroni correction for multiple testing.	Genotypes CG + GG are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	22441531	981502054
CASP7	rs4353229	CC + CT	docetaxel	efficacy	yes	Patients with the CC and CT genotypes had increased overall survival time compared to those with the TT genotype. p-value remained significant after Bonferroni correction for multiple testing. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	22441531	981502079
CASP7	rs12415607	AA + AC	gemcitabine	efficacy	no	No significant association was seen with overall survival time. This was a stratified analysis of only people taking gemcitabine, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes AA + AC are not associated with response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	22441531	981502647
CASP7	rs4353229	CC + CT	gemcitabine	efficacy	no	No significant association was seen with overall survival time. This was a stratified analysis of only people taking gemcitabine, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes CC + CT are not associated with response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	22441531	981502663
CASP7	rs12415607	AA + AC	docetaxel	efficacy	yes	Patients with the AA and AC genotypes had increased overall survival time compared to those with the CC genotype.	Genotypes AA + AC are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	22441531	981502071
CASP7	rs1127687	AA + AG	gemcitabine	efficacy	yes	Patients with the AA and AG genotypes had reduced progression-free survival compared to those with the GG genotype. This was a stratified analysis of only people taking gemcitabine, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes AA + AG are associated with decreased response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	22441531	981502697
CASP7	rs1127687	AA + AG	paclitaxel	efficacy	yes	Patients with the AA and AG genotypes had reduced progression-free survival compared to those with the GG genotype. This was a stratified analysis of only people taking paclitaxel, out of the original study cohort of 663 people taking a variety of chemotherapeutic drugs.	Genotypes AA + AG are associated with decreased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	22441531	981502687